Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window As explained by ...

Patiromer oral suspension, an investigational drug, was found to reduce elevated potassium levels in patients with chronic diabetic kidney disease. Findings from the study are published in the Journal ...

Hyperkalemia treatment trends in the ED are varied and inconsistent, depending on potassium levels when patients reach the ED. Although various treatments decreased potassium over 4 hours, only ...

It can be administered orally or in an enema. ANI Pharmaceuticals announced the launch of Kionex ® (sodium polystyrene sulfonate suspension USP) for Oral or Rectal Use for the treatment of ...

Postoperative hyperkalemia is an important complication of adrenalectomy for aldosterone-producing adenoma. Recently, postoperative hyperkalemia has been found to have a relatively high incidence ...

WILMINGTON, Del.--(BUSINESS WIRE)--Today, the US Food and Drug Administration (FDA) approved a label update in the US for AstraZeneca’s LOKELMA ® (sodium zirconium cyclosilicate) to include a dosing ...

In a European study, approximately one-third of hospitalizations involving patients with recurrent hyperkalemia directly related to serum potassium elevation. Recurrent hyperkalemia is a major cause ...

Objectives: This study examined renin-angiotensin-aldosterone system (RAAS) inhibitor dose levels in a US patient population and investigated the impact of hyperkalemia on RAAS inhibitor dose and the ...

Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure in the United States have hyperkalemia In clinical trials, Veltassa significantly reduced blood potassium and kept ...

G_hyperkalemia_web How much do your patients know about the dangers of high potassium levels in the body? They may know that potassium is good for you, or that you need specific levels of it in the ...

Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, today announced the initiation of a Phase 3 ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Today, the US Food and Drug Administration (FDA) approved a label update in the US for AstraZeneca’s LOKELMA® (sodium zirconium cyclosilicate) to include a dosing ...